Sanofi-Aventis SA (ADR) (NYSE:SNY), France’s biggest pharmaceutical group has accused Hospira Inc and Canada’s Apotex Inc of infringing patents for the cancer drug Taxotere. Sanofi-Aventis has said that both the companies have tried to copy their products. Earlier Sanofi-Aventis have filed separate complaints against Hospira Inc and Apotex Inc that they have violated the patent laws and have attempted to duplicate their top ranging product that is developed and marketed for the treatment of cancer patients. Though the market reacted sharply after the news broke into the market, but there was not much of fluctuation in the shares of Sanofi-Aventis at the end of the day.

Sanofi-Aventis is one of the leading pharmaceutical companies in France and globally as well. The company is into the research, development, manufacturing

...

In the great state of Tennessee, there is a company that is on the cutting edge of cancer research and has taken their technology worldwide in an attempt to help cure the disease. The company is Provectus Pharmaceuticals and if they achieve continued success, they may soon be a well known name.

Provectus Pharmaceuticals is a development-stage oncology and dermatology biopharmaceutical company which uses the agent PV-10 as a therapeutic agent for a broad spectrum of cancers. Currently, PV-10 is available for select cancer patients in the U.S. but the program was initiated in Australia in June of 2009 and has excelled across the globe.

In the U.S., the PV-10 program commenced at St. Luke’s Hospital and Health Network in Bethlehem, PA under the watchful eye of the renowned Dr. Sanjiv Agarwaia who served as the Principal Investigator at that site for the Phase 2 Melanoma Trial. The U.S.

...

Yesterday, Bristol-Myers Squibb (BMY) released inconsistent results for its colon cancer drug Erbitux (cetuximab) from two late-stage studies. Among the two retrospective analyses of the pivotal phase III studies, CRYSTAL and COIN, one reported positive results while the other failed to meet its primary end point. Erbitux is sold by Merck KGaA, Eli Lilly (LLY) and Bristol-Myers Squibb.

CRYSTAL is a multi-national study conducted by Merck KGaA. Erbitux, when added to Folfiri (a chemotherapy regimen) increased median overall survival to 19.9 months in an intent-to-treat population of first-line metastatic colorectal cancer (mCRC) patients compared to 18.6 months in the recipients of Folfiri only.

Moreover, when studied in a subset of mCRC patients with normal or wild-type version of a gene called KRAS, the median overall survival increased to 23.5 months in patients who received Erbitux plus Folfiri as against 20 months for those who took Folfiri alone.

...